Nektar Q4 2021 Earnings Report
Key Takeaways
Nektar Therapeutics reported revenue of $25.0 million and a net loss of $145.6 million for the fourth quarter of 2021. The company's cash and investments in marketable securities were approximately $0.8 billion at the end of the year. Nektar is advancing its clinical pipeline in oncology, immunology, and virology.
Revenue for the fourth quarter of 2021 was $25.0 million, compared to $23.5 million in the fourth quarter of 2020.
Total operating costs and expenses in the fourth quarter of 2021 were $137.9 million, compared to $134.2 million in the fourth quarter of 2020.
R&D expense in the fourth quarter of 2021 was $99.6 million, compared to $102.7 million for the fourth quarter of 2020.
Net loss for the fourth quarter of 2021 was $145.6 million, or $0.79 basic and diluted loss per share, compared to a net loss of $117.2 million, or $0.65 basic and diluted loss per share in the fourth quarter of 2020.
Nektar
Nektar
Forward Guidance
Nektar expects topline results from three registrational trials evaluating bempegaldesleukin in combination with a checkpoint inhibitor in melanoma, renal cell carcinoma and bladder cancer in the first half of 2022.